156 related articles for article (PubMed ID: 19900844)
21. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
[TBL] [Abstract][Full Text] [Related]
22. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
[TBL] [Abstract][Full Text] [Related]
23. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
24. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy.
Becher B; Giacomini PS; Pelletier D; McCrea E; Prat A; Antel JP
Ann Neurol; 1999 Feb; 45(2):247-50. PubMed ID: 9989628
[TBL] [Abstract][Full Text] [Related]
25. Differential changes in CD4+ and CD8+ effector and regulatory T lymphocyte subsets in the testis of rats undergoing autoimmune orchitis.
Jacobo P; Guazzone VA; Jarazo-Dietrich S; Theas MS; Lustig L
J Reprod Immunol; 2009 Jul; 81(1):44-54. PubMed ID: 19520436
[TBL] [Abstract][Full Text] [Related]
26. CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis.
McKay FC; Swain LI; Schibeci SD; Rubio JP; Kilpatrick TJ; Heard RN; Stewart GJ; Booth DR
J Autoimmun; 2008 Aug; 31(1):52-8. PubMed ID: 18406576
[TBL] [Abstract][Full Text] [Related]
27. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
28. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis.
Correale J; Villa A
J Neuroimmunol; 2008 Mar; 195(1-2):121-34. PubMed ID: 18234356
[TBL] [Abstract][Full Text] [Related]
29. T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis.
Iorio R; Frisullo G; Nociti V; Patanella KA; Bianco A; Marti A; Mirabella M; Tonali PA; Batocchi AP
Clin Immunol; 2009 Apr; 131(1):70-83. PubMed ID: 19097824
[TBL] [Abstract][Full Text] [Related]
30. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
31. IFNbeta therapy progressively normalizes the increased ex vivo T lymphocyte apoptosis observed in active patients with multiple sclerosis.
García-Merino A; Barcenilla H; Díaz D; Monserrat J; Prieto A; Alvarez-Mon M;
Clin Immunol; 2009 Aug; 132(2):195-202. PubMed ID: 19443275
[TBL] [Abstract][Full Text] [Related]
32. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate.
Chiarini M; Sottini A; Ghidini C; Zanotti C; Serana F; Rottoli M; Zaffaroni M; Bergamaschi R; Cordioli C; Capra R; Imberti L
Mult Scler; 2010 Feb; 16(2):218-27. PubMed ID: 20007428
[TBL] [Abstract][Full Text] [Related]
33. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
34. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
[TBL] [Abstract][Full Text] [Related]
35. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
36. Changes in T-cell subpopulations during four years of suppression of HIV-1 replication in patients with advanced disease.
Lepej SZ; Begovac J; Vince A
FEMS Immunol Med Microbiol; 2006 Apr; 46(3):351-9. PubMed ID: 16553807
[TBL] [Abstract][Full Text] [Related]
37. Thymic output and peripheral T lymphocyte subsets in relapsing--remitting multiple sclerosis patients treated or not by IFN-beta.
Puissant-Lubrano B; Viala F; Winterton P; Abbal M; Clanet M; Blancher A
J Neuroimmunol; 2008 Jan; 193(1-2):188-94. PubMed ID: 18068811
[TBL] [Abstract][Full Text] [Related]
38. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
39. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.
Zhang X; Markovic-Plese S
Clin Neurol Neurosurg; 2010 Sep; 112(7):641-5. PubMed ID: 20570038
[TBL] [Abstract][Full Text] [Related]
40. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
